Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C. Verhagen CV, et al. Among authors: van den brekel mw. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. Radiother Oncol. 2015. PMID: 25981132
Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion.
Kartachova MS, Valdés Olmos RA, Haas RL, Hoebers FJ, van den Brekel MW, van Zandwijk N, Herk Mv, Verheij M. Kartachova MS, et al. Among authors: van den brekel mw, van zandwijk n. Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):893-9. doi: 10.1007/s00259-006-0070-1. Epub 2006 Apr 4. Eur J Nucl Med Mol Imaging. 2006. PMID: 16586080 Clinical Trial.
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. Heukelom J, et al. BMC Cancer. 2013 Feb 22;13:84. doi: 10.1186/1471-2407-13-84. BMC Cancer. 2013. PMID: 23433435 Free PMC article. Clinical Trial.
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy.
Keek S, Sanduleanu S, Wesseling F, de Roest R, van den Brekel M, van der Heijden M, Vens C, Giuseppina C, Licitra L, Scheckenbach K, Vergeer M, Leemans CR, Brakenhoff RH, Nauta I, Cavalieri S, Woodruff HC, Poli T, Leijenaar R, Hoebers F, Lambin P. Keek S, et al. PLoS One. 2020 May 22;15(5):e0232639. doi: 10.1371/journal.pone.0232639. eCollection 2020. PLoS One. 2020. PMID: 32442178 Free PMC article.
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH, van der Heijden M, Wesseling FWR, de Ruiter EJ, Heymans MW, Terhaard C, Vergeer MR, Buter J, Devriese LA, de Boer JP, Navran A, Hoeben A, Vens C, van den Brekel M, Brakenhoff RH, Leemans CR, Hoebers F. de Roest RH, et al. Among authors: van der heijden m, van den brekel m. Radiother Oncol. 2022 Oct;175:112-121. doi: 10.1016/j.radonc.2022.08.013. Epub 2022 Aug 13. Radiother Oncol. 2022. PMID: 35973619 Free article.
296 results